Main enrollment areas
clinical medicine, biology and data science
Research Content
Precision diagnosis and treatment of diabetes mellitus
Big Data and Smart Healthcare
Clinical and basic research on pan-vascular lesions
Clinical and basic research on metabolic liver disease
Jianping Weng, M.D., PhD, is an endocrinologist.
After obtaining his master and doctor degrees from Sun Yat-sen University, Dr. Weng received training as a physician and furthered his study at several institutes abroad, including Malmo General Hospital of Lund University in Sweden, the Joslin Diabetes Center of Harvard University in the United States, and St.Vincent's Hospital of University of New South Wales in Australia.
As the first to demonstrate the reversibility of pancreatic islet function among patients with newly diagnosed type 2 diabetes (T2DM) using short-term intensive insulin therapy (Diabetes Care 2004, 2011, Lancet 2008), Dr. Weng proposed and validated the theory of β cell restoration in T2DM, and took the lead in development and the dissemination of the Standards of Care for Type 2 Diabetes in China (Diabetes Metab Res Rev 2016). Besides, Dr. Weng also steered in building the international and domestic consensus of early intensive insulin treatment protocols for T2DM. In 2018, Dr. Weng and colleagues completed the first national representative report of the all-age incidence of type 1 diabetes (T1DM, BMJ 2018). And in 2021, he and colleagues reported that a prepregnancy-to-postpartum comprehensive management plan improved the pregnancy outcomes among women with T1DM (Diabetes Care 2021).
Committed to medical education, clinical practice, and scientific research for more than 35 years, Dr. Weng is currently a distinguished professor of the Yangtze River Scholar, a recipient of the National Outstanding Youth Fund. He is the Vice President of the Chinese Endocrinologist Association and the Honorary President of the Chinese Diabetes Society. Dr. Weng has published over 500 academic articles in journals including NEJM, the Lancet, The BMJ, Lancet Diabetes & Endocrinology, JCI, Diabetes Care, Hepatology, Diabetologia and Diabetes, with a total citation frequency of more than 27,000 times. He has been awarded the Elsevier China Highly Cited Scholar for four consecutive years from 2020 to 2023, and his findings have been cited in more than 60 guidelines/consensus around the globe, and cited in professional tools such as Williams Textbook of Endocrinology The research results have been cited in more than 60 guidelines/consensus around the world, and cited in Williams Textbook of Endocrinology, 14th edition, American Society of Endocrinology monographs and Clinical Endocrinology and other professional tools.He won numerous awards, including the Scientific Achievements Award, which is the highest academic award of the Chinese Diabetes Society in 2018.
Dr. Weng is the Editor-in-Chief of the Chinese Journal of Diabetes (Chinese version); an associated editor of Chinese Medical Journal (English), Journal of Diabetes, and Journal of Diabetes Investigation; and the Co-editor of Diabetes Metabolism Research and Reviews. He was also the member of international advisory board of The BMJ.
Education
1980.09 – 1985.06: Bachelor of Medicine, Southeast University Medical School (formerly Nanjing Railway Medical College)
1988.09 – 1991.06: Master of Clinical Medicine, Sun Yat-sen University (formerly Sun Yat-sen Medical University)
1993.09 – 1996.06: Doctor of Clinical Medicine, Sun Yat-sen University
1997.12 – 2000.03: Postdoctoral, Malmo General Hospital, Lund University, Sweden
2001.03 – 2001.04: Short-term visit, Joslin Diabetes Center, Harvard University, USA
2007.02 – 2007.08: Senior Visiting Scholar, St. Vincent’s Hospital, University of New South Wales, Australia
Work Experience
Work Experience: 1991.08~1997.10
1991.08~1997.10 Resident and Attending Physician, Department of Endocrinology, The First Affiliated Hospital of Sun Yat-sen University.
1997.11～2000.04 Deputy Director and Associate Professor, Department of Endocrinology, The First Affiliated Hospital of Sun Yat-sen University.
2000.05∼2007.10 Director, Professor, and Subject Leader, Department of Endocrinology, The First Affiliated Hospital of Sun Yat-sen University.
2007.11∼2018.09 First Discipline Leader and Vice President of National Key Discipline, The Third Hospital Affiliated to Sun Yat-sen University
2018.09 to 2019.10 Executive Dean, School of Clinical Medicine, University of Science and Technology of China, and Vice President of the First Affiliated Hospital
2019.10 to -2024.05 University of Science and Technology of China Vice Minister of Life Science and Medicine, Executive Dean of the School of Clinical Medicine, Vice Dean of the Affiliated No. 1 Hospital, and Executive Dean of CAS Clinical Research Hospital (Hefei)
2020.10∼2024.03 President of Bengbu Medical University
2018.09∼Present Chair Professor, University of Science and Technology of China
2024.03∼President of Anhui Medical University
Representative Papers (Last Five Years)
1) Luo S, Zheng X#, Bao W#, Nie S, Ding Y, Yue T, Zhou Y, Hu Y, Li H, Yang Q, Wan Q, Liu B, Xu H, Li G, Xu G, Chen C, Liu H, Shi Y, Zha Y, Kong Y, Su G, Tang Y, Gong M, Ji L*, Hou FF*, Weng J*. Real-world effectiveness of early insulin therapy on the incidence of cardiovascular events in newly diagnosed type 2 diabetes. Signal Transduct Target Ther. 2024 Jun 6;9(1):154. (JCR:Q1 CAS:I)
2) Xu S, Wu X, Wang S, Xu M, Fang T, Ma X, Chen M, Fu J, Guo J, Tian S, Tian T, Cheng X, Yang H, Zhou J, Wang Z, Yin Y, Xu W, Xu F, Yan J, Wang Z, Luo S, Zhang XJ, Ji YX, Weng J*. TRIM56 protects against nonalcoholic fatty liver disease by promoting the degradation of fatty acid synthase. J Clin Invest. 2024 Jan 11;134(5):e166149. (JCR:Q1 CAS:I)
3) Tan H, Shi Y, Yue T, Zheng D, Luo S, Weng J*, Zheng X*. Machine learning approach reveals microbiome, metabolome, and lipidome profiles in type 1 diabetes. J Adv Res. 2023 Nov 30:S2090-1232(23)00363-6.(JCR:Q1 CAS:I)
4) Gong Y, Luo S, Shi J, Wei T, Wang J, Liu Y, Yan J, Yang D, Li L, Sun Z, Zheng X, Weng J*. Preconception episodes of severe hypoglycemia and risk of adverse pregnancy outcomes in pregnant women with type 1 diabetes mellitus. Diabetes Metab Res Rev. 2024 Mar;40(3):e3741. (JCR:Q1 CAS:I)
5) Qin W, Weng J*. Hepatocyte NLRP3 interacts with PKCε to drive hepatic insulin resistance and steatosis. Sci Bull (Beijing). 2023 Jul 15;68(13):1413-1429. (JCR:Q1 CAS:I)
6) Xu S, Liu Y, Ding Y, Luo S, Zheng X, Wu X, Liu Z, Ilyas I, Chen S, Han S, Little PJ, Jain MK, Weng J*. The zinc finger transcription factor, KLF2, protects against COVID-19 associated endothelial dysfunction. Signal Transduct Target Ther. 2021 Jul 12;6(1):266.(JCR:Q1 CAS:I)
7) Jiang Z, Ren W, Liang H, Yan J, Yang D, Luo S, Zheng X, Lin GW, Xian Y, Xu W, Yao B, Noble JA, Bei JX, Groop L, Weng J*. HLA class I genes modulate disease risk and age at onset together with DR-DQ in Chinese patients with insulin-requiring type 1 diabetes. Diabetologia. 2021 Sep;64(9):2026-2036.(JCR:Q1 CAS:I)
8) Zheng X, Yang D, Luo S, Yan J, Guo X, Yang H, Bao W, Groop L, Dornhorst A, Weng J*. CARNATION Study Group. Association of Implementation of a Comprehensive Preconception-to-Pregnancy Management Plan With Pregnancy Outcomes Among Chinese Pregnant Women With Type 1 Diabetes: The CARNATION Study. Diabetes Care. 2021 Apr;44(4):883-892. (JCR:Q1 CAS:I)
9) Zheng X, Luo S, Sun Y, Han M, Liu J, Sun L,Zhang L,Ling P,Ding Y,Jin T, Liu Z,Weng J*. Asymptomatic patients and asymptomatic phases of Coronavirus Disease 2019 (COVID-19): a population-based surveillance study. Natl Sci Rev.2020;7(10):1527-39. (JCR:Q1 CAS:I)
10) Yan J, Yao B, Kuang H, Yang X, Huang Q, Hong T, Li Y, Dou J, Yang W, Qin G, Yuan H, Xiao X, Luo S, Shan Z, Deng H, Tan Y, Xu F, Xu W, Zeng L, Kang Z, Weng J*. Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. Hepatology. 2019 Jun;69(6):2414-2426.(JCR:Q1 CAS:I)
Laboratory Website
http://ioemd.ustc.edu.cn
Contact Information
E-mail: ioemdoffice@ustc.edu.cn
Phone: 0551-63602683